Search results
Results from the WOW.Com Content Network
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
An FDA-approved weight loss medication, naltrexone-bupropion is generally considered effective and safe to use. You may experience side effects like dizziness, mood changes, trouble sleeping, and ...
In the United States, semaglutide (Wegovy) is approved by the FDA for chronic weight management. [50] The FDA guidelines say that a therapy may be approved if it results in weight loss that is statistically significant greater than placebo and generally at least five percent of body weight over six months that comes predominantly from fat mass.
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...
The FDA said Novo Nordisk's semaglutide, which is sold as Ozempic to treat diabetes and Wegovy for weight loss, remains on the agency's drug shortage list even though all versions of the drug are ...
Recently, two pharmaceutical giants received FDA approval for a new treatment for type 2 diabetes. Farxiga (dapagliflozin) is a "sodium-glucose co-transporter 2 inhibitor", or SGLT2 inhibitor for ...
Diabetes treatment Mounjaro has been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far outstripped supply. The limited ...